



# CARD9+ Microglia Orchestrate Antifungal Immunity via IL-1 and CXCL1-mediated Neutrophil Recruitment

Drummond, Rebecca A.; Swamydas, Muthulekha; Oikonomou, Vasileios; Zhai, Bing; Dambuza, Ivy M.; Schaefer, Brian C.; Bohrer, Andrea C.; Mayer-barber, Katrin D.; Lira, Sergio A.; Iwakura, Yoichiro; Filler, Scott G.; Brown, Gordon D.; Hube, Bernhard; Naglik, Julian R.; Hohl, Tobias M.; Lionakis, Michail S.

DOI:

[10.1038/s41590-019-0377-2](https://doi.org/10.1038/s41590-019-0377-2)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Drummond, RA, Swamydas, M, Oikonomou, V, Zhai, B, Dambuza, IM, Schaefer, BC, Bohrer, AC, Mayer-barber, KD, Lira, SA, Iwakura, Y, Filler, SG, Brown, GD, Hube, B, Naglik, JR, Hohl, TM & Lionakis, MS 2019, 'CARD9<sup>+</sup> Microglia Orchestrate Antifungal Immunity via IL-1 and CXCL1-mediated Neutrophil Recruitment', *Nature Immunology*, vol. 20, no. 5, pp. 559–570. <https://doi.org/10.1038/s41590-019-0377-2>

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

Checked for eligibility: 14/03/2019

This is the accepted manuscript for a forthcoming publication in Nature Immunology.

This document is subject to Springer Nature re-use terms:

<https://www.nature.com/authors/policies/license.html#terms>

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

**CARD9<sup>+</sup> Microglia Orchestrate Antifungal Immunity via IL-1 $\beta$  and CXCL1-mediated Neutrophil Recruitment**

**CARD9<sup>+</sup> Microglia Promote Antifungal Immunity via IL-1 $\beta$  and CXCL1-mediated Neutrophil Recruitment**

**CARD9<sup>+</sup> Microglia Protect against Fungal Invasion via IL-1 $\beta$  and CXCL1-mediated Neutrophil Recruitment**

Rebecca A. Drummond<sup>1\*†</sup>, Muthulekha Swamydas<sup>1#</sup>, Vasileios Oikonomou<sup>1#</sup>, Bing Zhai<sup>2#</sup>, Ivy M. Dambuza<sup>3</sup>, Brian C. Schaefer<sup>4</sup>, Andrea C. Bohrer<sup>5</sup>, Katrin D. Mayer-Barber<sup>5</sup>, Sergio A. Lira<sup>6</sup>, Yoichiro Iwakura<sup>7</sup>, Scott G. Filler<sup>8</sup>, Gordon D. Brown<sup>3</sup>, Bernhard Hube<sup>9,10</sup>, Julian R. Naglik<sup>11</sup>, Tobias M. Hohl<sup>2</sup>, Michail S. Lionakis<sup>1\*</sup>

<sup>1</sup>Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy & Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA

<sup>2</sup>Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

<sup>3</sup>Medical Research Council Centre for Medical Mycology at the University of Aberdeen, Aberdeen Fungal Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK

<sup>4</sup>Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814

<sup>5</sup>Inflammation and Innate Immunity Unit, LCIM, NIAID, NIH, Bethesda, MD, USA

<sup>6</sup>Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

<sup>7</sup>Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan

<sup>8</sup>Division of Infectious Diseases, Department of Medicine, Los Angeles Biomedical Research Institute at Harbor—UCLA, Torrance, CA, 90502

26 <sup>9</sup>Department of Microbial Pathogenicity Mechanisms; Leibniz Institute for Natural Product Research and Infection  
27 Biology; Hans Knöll Institute Jena; Jena, Germany  
28 <sup>10</sup>Friedrich Schiller University, Jena, Germany  
29 <sup>11</sup>Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College  
30 London, London, United Kingdom  
31 †Current address: Institute of Immunology & Immunotherapy, Institute of Microbiology & Infection, University of  
32 Birmingham, Birmingham B15 2TT, UK  
33 #These authors contributed equally to this work  
34 \*Correspondence: [r.drummond@bham.ac.uk](mailto:r.drummond@bham.ac.uk); [lionakism@niaid.nih.gov](mailto:lionakism@niaid.nih.gov)

## 35 **Abstract**

36

37 The C-type lectin receptor/Syk adaptor CARD9 facilitates protective antifungal immunity within  
38 the central nervous system (CNS), as human CARD9-deficiency causes fungal-specific CNS-  
39 targeted infection susceptibility. CARD9 is required for neutrophil recruitment to the fungal-  
40 infected CNS, which mediates fungal clearance. Here, we investigated host and pathogen  
41 factors that promote protective neutrophil recruitment during *Candida albicans* CNS invasion.  
42 IL-1 $\beta$  was essential for CNS antifungal immunity by driving CXCL1 production, which recruited  
43 CXCR2-expressing neutrophils. Neutrophil-recruiting IL-1 $\beta$  and CXCL1 production was  
44 induced in microglia by the fungal-secreted toxin Candidalysin, in a p38-cFos-dependent  
45 manner. Importantly, microglia relied on CARD9 for production of IL-1 $\beta$ , via both *Il1b*  
46 transcriptional regulation and inflammasome activation, and of CXCL1 in the fungal-infected  
47 CNS. Microglia-specific *Card9* deletion impaired IL-1 $\beta$  and CXCL1 production and neutrophil  
48 recruitment, and increased CNS fungal proliferation. Taken together, an intricate network of  
49 host-pathogen interactions promotes CNS antifungal immunity, which is impaired in human  
50 CARD9-deficiency leading to CNS fungal disease.

## 51 **Introduction**

52

53 The CNS is invaded by microorganisms during systemic infections, yet the mechanisms of  
54 CNS-specific anti-microbial immunity remain poorly-understood. This is particularly true for  
55 CNS fungal infections, which present unmet diagnostic and treatment challenges, leading to  
56 unacceptably high mortality (>50%)<sup>1</sup>. Fungal CNS invasion is enhanced by fungal-specific risk  
57 factors, including HIV infection, neutropenia, corticosteroid use, and Bruton's tyrosine kinase  
58 inhibition<sup>1</sup>. However, the most striking human risk factor for selective CNS fungal infection  
59 susceptibility is inherited deficiency of the C-type lectin receptor (CLR)–Syk adaptor CARD9.

60

61 CARD9 relays fungal-sensing signals downstream of the CLR superfamily of pattern  
62 recognition receptors, including Dectin-1, Dectin-2, Dectin-3 and Mincle. Syk kinase is  
63 recruited to phosphorylated ITAM sequences of CLRs or their signaling partner FcR $\gamma$  to form  
64 the CARD9-BCL10-MALT1 signalosome, which activates downstream effectors including  
65 NF $\kappa$ B, NLRP3 inflammasome and MAPK signaling.

66

67 CARD9-deficient patients manifest fungal-specific infection susceptibility, predominantly in the  
68 CNS by *Candida albicans*<sup>2, 3, 4</sup>. We previously showed that CARD9-deficiency in humans and  
69 mice confers a fungal- and brain-specific defect in neutrophil recruitment, which is detrimental  
70 for control of CNS fungal invasion<sup>5</sup>. However, the CNS cellular and molecular cues that  
71 promote protective neutrophil recruitment during *C. albicans* invasion and their dependence on  
72 CARD9 *in vivo* remain unknown.

73

74 Herein, we systematically investigated host and pathogen factors that promote protective  
75 neutrophil influx into the *C. albicans*-infected CNS to better understand the pathogenesis of  
76 human CARD9-deficiency. We uncover an intricate pathway by which the *C. albicans*-secreted  
77 toxin Candidalysin engages microglia to produce IL-1 $\beta$  and CXCL1 for protective recruitment of  
78 CXCR2-expressing neutrophils. Importantly, microglial IL-1 $\beta$  and CXCL1 production depends  
79 on CARD9 and specific deletion of microglial CARD9 impairs neutrophil recruitment to the *C.*  
80 *albicans*-infected CNS. Collectively, our data unveil complex host-pathogen interactions that  
81 recruit protective neutrophils during fungal CNS invasion and reveal the mechanism that  
82 underlies CNS fungal susceptibility in CARD9-deficiency.

## Results

### CLR Functional Redundancy during Fungal CNS Invasion

As previously shown, CARD9 is essential for protective CNS immunity against *C. albicans*, principally through promoting early neutrophil recruitment (**Fig. 1a**). We first investigated the relative contribution of CARD9-coupled CLRs, which are expressed by brain-resident microglia (**Supplementary Fig. 1**), in mediating this protective neutrophil recruitment. We infected mice deficient in Dectin-1 (*Clec7a*<sup>-/-</sup>), Dectin-2 (*Clec4e*<sup>-/-</sup>), Dectin-3 (*Clec4d*<sup>-/-</sup>) and Mincle (*Clec4e*<sup>-/-</sup>) and measured brain neutrophil accumulation at 24 h post-infection (**Supplementary Fig. 2**). We chose this time-point since it is the peak of the neutrophil response in wild-type animals and neutrophil depletion at this time-point increases susceptibility to brain fungal invasion<sup>5</sup>.

Animals individually deficient in CARD9-coupled CLRs recruited neutrophils to the infected brain normally (**Fig. 1b**). Despite this, we observed increases in fungal brain burdens at 72 h post-infection in mice deficient in Dectin-1 or Dectin-2 but not Dectin-3 or Mincle (**Fig. 1c**), suggesting that Dectin-1 and Dectin-2 employ neutrophil recruitment-independent mechanisms to protect against brain fungal proliferation. Indeed, brain-infiltrating neutrophils from Dectin-1 and Dectin-2-deficient animals exhibited reduced fungal phagocytosis (**Supplementary Fig. 3**), consistent with prior findings<sup>6</sup>.

To activate CARD9-dependent signaling, phosphorylation occurs on the ITAM sequence within the intracellular tail of Dectin-1 or FcR $\gamma$ , which Dectin-2, Dectin-3 and Mincle associate with. Therefore, we assessed whether deletion of all four CLRs affected the neutrophil response in

106 the infected brain. We used mice doubly-deficient in Dectin-1 and FcR $\gamma$  (*Clec7a*<sup>-/-</sup>*Fcerg1*<sup>-/-</sup>)  
107 and found that loss of both Dectin-1 and the FcR $\gamma$ -coupled CLRs phenocopied Card9-  
108 deficiency with significantly decreased neutrophil recruitment and corresponding increased  
109 brain fungal burdens (**Fig. 1b,c**). Taken together, CARD9-coupled CLRs functionally  
110 compensate to mediate neutrophil recruitment-dependent protection against *C. albicans* CNS  
111 invasion.

### 112 113 **MALT1 is Required for Defense against CNS Candidiasis**

114 The CARD9-MALT1-BCL10 signalosome is necessary for transducing fungal-sensing  
115 intracellular signals. Human deficiencies of MALT1 or BCL10 cause defective innate and  
116 adaptive immune responses, and many of these patients die in childhood from bacterial and  
117 viral infections<sup>2</sup>. Human MALT1-deficiency additionally manifests with mucosal candidiasis,  
118 suggesting that antifungal immunity is impaired in these patients. However, whether MALT1-  
119 deficiency also predisposes to brain-targeted candidiasis is unknown. To test this, we infected  
120 *Malt1*-deficient mice and assessed control of CNS *C. albicans* growth. *Malt1*<sup>-/-</sup> animals  
121 recruited neutrophils to the brain similarly to wild-type, however these animals exhibited  
122 uncontrolled brain fungal growth at 72 h post-infection (**Fig. 1d**). Therefore, MALT1 is critical  
123 for protective CNS immunity against *C. albicans*; however, the MALT1-dependent protective  
124 mechanisms operating in this tissue are independent of neutrophil recruitment, unlike CARD9.

### 125 126 ***Candida* Drives CNS Neutrophil Influx via IL-1 $\beta$ and CXCL1**

127 To determine the local cues that recruit protective neutrophils in the infected CNS, we  
128 examined key cytokine and chemokine circuits using gene-deficient mice. We began by



129 infecting IL-1 receptor (IL-1R)-deficient mice, because production of IL-1 $\beta$  by human peripheral  
130 blood mononuclear cells upon fungal stimulation depends on CARD9<sup>5, 7</sup>, and because IL-1R  
131 was previously shown to promote neutrophil recruitment to fungal-infected mucosal tissues<sup>8, 9</sup>,  
132 and to the bacterial-infected brain<sup>10</sup>. Upon *C. albicans* challenge, IL-1R-deficient mice  
133 phenocopied Card9-deficient mice, with a loss of early brain neutrophil recruitment and  
134 accompanying increased fungal brain burdens (**Fig. 2a,b**). Consistent with this, loss of the IL-  
135 1R signaling adaptor MyD88 caused similar defects in recruiting neutrophils and controlling  
136 fungal proliferation in the infected brain (**Fig. 2a,b**).

137

138 We next assessed which IL-1R ligands were important for driving CNS protection by infecting  
139 mice deficient in IL-1 $\alpha$ , IL-1 $\beta$  or both. Mice lacking IL-1 $\alpha$  had a small reduction in neutrophil  
140 numbers and a slight increase in fungal brain burden at 24 h post-infection (**Fig. 2a,b**).  
141 However, the lack of IL-1 $\alpha$  appeared to be compensated by IL-1 $\beta$ , since *Il1a*<sup>-/-</sup> animals  
142 recovered and controlled fungal brain infection similar to wild-type by 72 h post-infection (**Fig.**  
143 **2b**). In keeping with the critical contribution of IL-1 $\beta$ , mice deficient in IL-1 $\beta$ , or both IL-1 $\alpha$ /IL-  
144 1 $\beta$ , exhibited significantly reduced neutrophil accumulation and were highly susceptible for  
145 fungal brain invasion (**Fig. 2a,b**). Therefore, IL-1 $\beta$  is a critical mediator of neutrophil  
146 recruitment to promote control of *C. albicans* brain infection.

147

148 Downstream of IL-1R, the production of local chemotactic mediators recruits immune cells to  
149 infected tissues. Previously, we showed that the CNS-neutropenia observed in mouse and  
150 human CARD9-deficiency is not caused by neutrophil-intrinsic chemotaxis defects<sup>5</sup>, but rather  
151 by insufficient local production of soluble chemotactic mediators. However, which among the

152 several chemoattractants and their receptors recruit(s) protective neutrophils to the *C.*  
153 *albicans*-infected CNS is unknown.

154

155 CARD9 was shown to drive production of the CXCR2 ligands CXCL1 and CXCL2 during  
156 inflammatory arthritis<sup>11</sup> and murine subcutaneous phaeohyphomycosis<sup>12</sup>. During systemic *C.*  
157 *albicans* infection, CCR1 drives renal neutrophil accumulation and immune-related kidney  
158 destruction<sup>13</sup>, the leukotriene B4 (LTB<sub>4</sub>) receptor LTB4R1 promotes detrimental pulmonary  
159 neutrophil accumulation<sup>14</sup>, and CXCR1 mediates neutrophil-dependent fungal killing in the  
160 kidney<sup>15</sup>. However, the role of these receptors in CNS anti-*Candida* immunity is unknown,  
161 while CXCR2 and fMet-Leu-Phe (fMLP) receptor FPR1 have not been examined in anti-  
162 *Candida* defense.

163

164 To test the relative dependence on these major neutrophil-targeted chemoattractant receptors  
165 in protecting the fungal-infected brain, we infected mice deficient in CCR1, CXCR1, CXCR2,  
166 LTB4R1 or FPR1 and measured neutrophil recruitment and fungal brain burdens. We found no  
167 involvement of the CCL3–CCR1, CXCL5–CXCR1, LTB<sub>4</sub>–LTB4R1 or fMLP–FPR1 axes in  
168 controlling fungal brain infection, in line with normal early neutrophil recruitment in infected  
169 *Ccr1*<sup>-/-</sup>, *Cxcr1*<sup>-/-</sup>, *Ltb4r1*<sup>-/-</sup> and *Fpr1*<sup>-/-</sup> animals (**Fig. 2c,d and Supplementary Fig. 4**). In  
170 contrast, CXCR2-deficient mice had significantly reduced neutrophil accumulation and  
171 corresponding significantly increased fungal brain growth (**Fig. 2c,d**). These data demonstrate  
172 the importance of the CXCR2 axis in neutrophil-mediated protection against *C. albicans* brain  
173 infection.

174

175 Next, we wondered which CXCR2 ligand may recruit protective neutrophils to the fungal-  
176 infected brain. We infected *Cxcl1*<sup>-/-</sup> mice that lack expression of the potent neutrophil  
177 chemoattractant CXCL1. Notably, these animals had decreased neutrophil recruitment to the  
178 brain post-infection and exhibited a similar CNS invasion susceptibility phenotype to the *Cxcr2*<sup>-/-</sup>  
179 mice (**Fig. 2c,d**). Therefore, the CXCL1/CXCR2 chemokine axis is critical for protection  
180 against *C. albicans* brain invasion by recruiting protective neutrophils. Importantly, this data  
181 indicates that the reduced CXCL1 in the human CARD9-deficient *C. albicans*-infected CSF is  
182 biologically relevant and significant<sup>5</sup>.

183

#### 184 **IL-1 $\beta$ Activates CXCL1 in the Fungal-Infected Brain**

185 Since both IL-1 $\beta$  and CXCL1 were required for protection, we investigated whether their  
186 activation in the infected brain was simultaneous or sequential. We measured IL-1 $\beta$  and  
187 CXCL1 in brain homogenates at 24 h post-infection in animals lacking these inflammatory  
188 mediators using ELISA. We found no defect in IL-1 $\beta$  levels in CXCL1-deficient infected brains;  
189 however, we discovered a significant defect in CXCL1 production in the absence of IL-1 $\beta$  (**Fig.**  
190 **3a**). To define the IL-1 $\beta$ -dependent brain cellular sources of CXCL1, we infected wild-type and  
191 IL-1 $\beta$ -deficient mice and used intracellular flow cytometry. CXCL1 and pro-IL-1 $\beta$  were  
192 produced by multiple myeloid phagocytes in the fungal-infected brain, including resident  
193 microglia, the most numerous immune cells in the brain, recruited Ly6C<sup>hi</sup> monocytes which  
194 have been implicated in controlling *C. albicans* CNS invasion<sup>16</sup>, and neutrophils themselves  
195 (**Fig. 3b**). Interestingly, *Il1b*<sup>-/-</sup> microglia recovered from *C. albicans*-infected brains had a  
196 profound defect in CXCL1 production, exhibiting significant reductions under every *ex vivo*  
197 restimulation condition tested (**Fig. 3c**). Ly6C<sup>hi</sup> monocytes isolated from *Il1b*<sup>-/-</sup> *C. albicans*-

198 infected brains produced less CXCL1 when restimulated *ex vivo* with LPS, with no differences  
199 detected under non-stimulated or zymosan-stimulated conditions. Neutrophil production of  
200 CXCL1 did not differ between the two mouse groups (**Fig. 3c**). Therefore, IL-1 $\beta$  is required for  
201 subsequent CXCL1 production from resident microglia and recruited monocytes, which in turn  
202 recruits CXCR2-expressing neutrophils to the fungal-infected brain (**Fig. 2c**).

### 203 204 **Candidalysin is a Fungal Avirulence Factor in the Brain**

205 Use of genetically-deficient mice allowed us to map the host pathway promoting protection  
206 against *C. albicans* brain infection, in which IL-1 $\beta$ –IL-1R–MyD88 signaling activates CXCL1  
207 production by resident microglia and recruited monocytes to mobilize neutrophils into the CNS.  
208 To identify the pathogen-associated factors that induce this protective host pathway, we  
209 infected animals with *C. albicans* strains lacking known virulence factors and assessed  
210 neutrophil recruitment and IL-1 $\beta$  and CXCL1 production in the infected brain.

211  
212 *C. albicans* hyphae are the predominant CNS-invasive morphology of *C. albicans*<sup>5</sup> and hyphal  
213 formation is associated with important virulence traits such as toxin and protease production,  
214 adhesion, invasion, and immune system activation<sup>17</sup>. Thus, we first asked whether neutrophil  
215 recruitment was impaired during infection with the *hgc1* $\Delta/\Delta$  *C. albicans* strain which cannot  
216 filament *in vivo*<sup>18</sup>. Indeed, infection with hypha-deficient *hgc1* $\Delta/\Delta$  *C. albicans* significantly  
217 impaired neutrophil recruitment and enhanced fungal CNS tissue invasion relative to the  
218 isogenic wild-type *C. albicans* strain (**Fig. 4a**). Thus, filamentation is strikingly not required for  
219 *C. albicans* invasion of brain tissue, in contrast to other organs such as the kidney<sup>18</sup>.

220

221 Candidalysin is a recently-described peptide toxin encoded by *ECE1* and expressed  
222 exclusively by *C. albicans* hyphae<sup>19</sup>. Candidalysin was shown to mediate epithelial cell  
223 damage via pore formation in the plasma cell membrane resulting in IL-1 $\alpha$  release and pro-  
224 inflammatory cytokine production. Hence, Candidalysin-null mutants were highly attenuated in  
225 murine oropharyngeal and vulvovaginal candidiasis models<sup>19, 20, 21</sup>. Instead, we found that lack  
226 of Candidalysin promoted brain infection, and that this phenotype was specific to the  
227 Candidalysin peptide since mutant strains deficient in the entire gene (*ece1* $\Delta/\Delta$ ) or specifically  
228 in the Candidalysin-encoding portion of the gene (*ece1* $\Delta/\Delta$  + *ECE1* $\Delta_{184-279}$ ) were both hyper-  
229 virulent for *C. albicans* brain invasion (**Fig. 4b**).

230

231 The increased ability of the Candidalysin-null mutants to proliferate within the brain directly  
232 correlated with the degree of neutrophil recruitment. We found a near absence of neutrophils in  
233 the brains of wild-type animals infected with Candidalysin-null strains and observed hyphal  
234 forms growing in the brain parenchyma with no neutrophilic reaction (**Fig. 4c**). In contrast, the  
235 Candidalysin-producing parental strain and the re-integrant control strain promoted neutrophil  
236 recruitment at 24 h post-infection, and these neutrophils clustered around invading hyphae  
237 (**Fig. 4c**). In line with the absence of neutrophils in the brains of mice infected with  
238 Candidalysin-null strains, IL-1 $\beta$  and CXCL1 were significantly reduced in brain homogenates  
239 from animals infected with these strains (**Fig. 4d**). Therefore, Candidalysin is a key fungal  
240 factor that activates the IL-1 $\beta$ –CXCL1 protective pathway *in vivo*. Notably, in contrast to its role  
241 in the mucosa, Candidalysin acts as an avirulence factor in the brain by instigating protective  
242 host CNS immunity, underscoring the tissue-specific opposing roles that a microbial factor may  
243 play during infection with the same pathogen<sup>17</sup>.

244

245 We next wondered whether other *C. albicans* hyphae-associated secreted proteins also  
246 activate protective neutrophil responses in the brain. Secreted aspartyl proteases (Saps) are  
247 enzymes with extracellular proteolytic activity and are linked to virulence<sup>22</sup>. *C. albicans* Saps  
248 promote neutrophil recruitment during vulvovaginal candidiasis in mice<sup>23, 24</sup>. Expression of the  
249 *SAP4-6* subfamily is coordinately regulated with hyphal formation<sup>22</sup>, therefore we tested  
250 whether these hyphal-associated Saps contributed towards virulence during brain invasion.  
251 Wild-type animals infected with the triple-deficient strain *sap4/5/6Δ/Δ* had comparable brain  
252 fungal burdens to animals infected with the complemented control strain (**Fig. 4e**). In line with  
253 this, we saw no difference in CNS neutrophil recruitment in these animals, indicating that *C.*  
254 *albicans* Saps exhibit tissue-specific roles in promoting neutrophil recruitment during  
255 infection<sup>23, 24</sup> (**Fig. 4e**). Therefore, protective CNS neutrophil recruitment is activated by  
256 Candidalysin, and not by other *C. albicans* hyphae-secreted enzymes.

257

### 258 **Candidalysin Drives Microglial IL-1 $\beta$ and CXCL1 *in vivo***

259 Since Candidalysin activates host CNS immunity, we sought to define the Candidalysin-  
260 responsive CNS immune cells. We infected wild-type mice with either the parental strain of *C.*  
261 *albicans* (BWP17) or the Candidalysin-null strain (*ece1Δ/Δ*), and analyzed IL-1 $\beta$  and CXCL1  
262 production using intracellular flow cytometry at 24 h post-infection (**Fig. 5**).

263 Although all brain phagocytes produced both IL-1 $\beta$  and CXCL1, microglia were the only  
264 population to exhibit dependence on Candidalysin, since microglia isolated from *ece1Δ/Δ*-  
265 infected brains produced significantly less IL-1 $\beta$  and CXCL1 *ex vivo* (**Fig. 5a,b**). In contrast,  
266 Ly6C<sup>hi</sup> monocytes and neutrophils did not depend on Candidalysin for IL-1 $\beta$  and CXCL1

267 production, suggesting that other as-yet unidentified fungal factors activate this pathway in  
268 these phagocytes. Together, our data show that Candidalysin acts on microglia to stimulate IL-  
269 1 $\beta$  release, which in turn drives CXCL1 production that is required for protective neutrophil  
270 CNS recruitment.

271

## 272 **Candidalysin Drives Differing Glial IL-1 $\beta$ –CXCL1 *ex vivo***

273 To gain mechanistic insights into how microglia respond to Candidalysin, we cultured the  
274 microglia cell line BV-2<sup>25</sup> in the presence of synthetic Candidalysin and measured IL-1 $\beta$  and  
275 CXCL1 in the supernatants by ELISA. In line with our *in vivo* work, we found time- and dose-  
276 dependent IL-1 $\beta$  production by BV-2 cells in response to Candidalysin (**Fig. 6a**). However, we  
277 did not detect CXCL1 from BV-2 cells stimulated under these conditions. We first considered  
278 that this could be due to Candidalysin-induced damage that may prevent BV-2 cells from  
279 producing CXCL1 after IL-1 $\beta$  secretion. Indeed, as shown for epithelial cells<sup>19</sup>, Candidalysin  
280 mediated dose-dependent cell damage to BV-2 microglia (**Fig. 6b**). Alternatively, additional  
281 signals beyond IL-1 $\beta$ , derived from non-microglial CNS cells, might be required for microglial  
282 CXCL1 induction, acting *in trans*. To test this hypothesis, we co-cultured BV-2 cells with  
283 immortalized C8-D1A astrocytes in the presence of Candidalysin and measured IL-1 $\beta$  and  
284 CXCL1 in the supernatants. We chose astrocytes since they are known to respond to IL-1 $\beta$  to  
285 produce inflammatory mediators, including CXCL1, in other models of CNS inflammation<sup>26, 27,</sup>  
286 <sup>28</sup>. We found that astrocytes responded to Candidalysin to produce CXCL1 (**Fig. 6c**), but not  
287 IL-1 $\beta$  (data not shown), and that CXCL1 production significantly increased when astrocytes  
288 and microglia were co-cultured (**Fig. 6c**). To confirm that microglia are a relevant cellular  
289 source of CXCL1 detected during microglia-astrocyte co-culture, we performed intracellular

290 staining for CXCL1 and found that BV-2 microglia are significant producers of CXCL1 in  
291 response to Candidalysin, but only when astrocytes were present (**Fig. 6d**). Therefore,  
292 astrocytes provide additional signals to microglia that are needed for CXCL1 production in  
293 response to Candidalysin.

294

295 We next investigated the pathway activated by Candidalysin in BV-2 microglia to produce IL-  
296  $1\beta$ . Candidalysin was previously shown in epithelial cells to activate c-Fos, in a p38-dependent  
297 manner, and the phosphatase MKP-1<sup>20</sup>. We thus asked whether the same pathways are  
298 activated by Candidalysin in BV-2 microglia. We found that Candidalysin sequentially and  
299 dose-dependently activated MKP-1 and c-Fos (**Fig. 6e**), and chemical inhibition of p38 or c-  
300 Fos significantly reduced IL- $1\beta$  release by Candidalysin-stimulated BV-2 cells (**Fig. 6f**).

301 Therefore, microglia produce IL- $1\beta$  in response to Candidalysin via activation of p38 and c-  
302 Fos.

303

### 304 **The Microglia IL- $1\beta$ –CXCL1 Response Requires CARD9**

305 CARD9-deficiency is the only known risk factor that uniquely predisposes to CNS candidiasis  
306 in the absence of iatrogenic intervention<sup>2, 5</sup>. We first examined whether CARD9-deficiency  
307 causes developmental defects in resident microglia, but found no defects in abundance or  
308 activation markers at steady state in *Card9*<sup>-/-</sup> microglia, which accumulated in similar numbers  
309 as wild-type microglia after fungal infection (**Supplementary Fig. 5**). Since *C. albicans*  
310 activates the microglial IL- $1\beta$ –CXCL1 axis to regulate protective neutrophil CNS recruitment,  
311 we next analyzed the dependence on CARD9 for induction of this pathway in microglia post-  
312 infection *in vivo*. We hypothesized that CARD9 is required for these functions, as microglia



313 highly express CARD9 and we previously found reduced transcription of CXC chemokines by  
314 *Card9*<sup>-/-</sup> microglia harvested from the *C. albicans*-infected brain<sup>5</sup>. We infected *Card9*<sup>+/+</sup> and  
315 *Card9*<sup>-/-</sup> animals with wild-type Candidalysin-expressing *C. albicans*, isolated phagocytes from  
316 the brain and measured pro-IL-1 $\beta$  and CXCL1 production following *ex vivo* restimulation. We  
317 found significantly decreased frequencies of CXCL1<sup>+</sup> and pro-IL-1 $\beta$ <sup>+</sup> cells in the fungal-infected  
318 *Card9*<sup>-/-</sup> brain, and these decreases mapped to microglia (**Fig. 7a,b**).

319  
320 Since production and secretion of mature IL-1 $\beta$  depends on pro-IL-1 $\beta$  expression and  
321 consecutive inflammasome-dependent processing, we asked whether microglia depend on  
322 CARD9 for pro-IL-1 $\beta$  transcription and/or inflammasome activation. We FACS-sorted microglia  
323 from wild-type and *Card9*<sup>-/-</sup> infected brains, and examined *Il1b* transcription by qRT-PCR, and  
324 levels of pro-IL-1 $\beta$  and cleaved and pro-caspase-1 by immunoblot. We found significantly  
325 decreased *Il1b* transcription in *Card9*<sup>-/-</sup> microglia, which we confirmed at the protein level (**Fig.**  
326 **7c,d**). These data are in line with the reported CARD9-dependent pro-IL-1 $\beta$  transcription in  
327 bone marrow-derived dendritic cells post-viral infection<sup>29</sup>. We also found significantly reduced  
328 cleaved caspase-1 in *Card9*<sup>-/-</sup> microglia (**Fig. 7d**), indicating that Card9 also operates at the  
329 level of inflammasome activation for IL-1 $\beta$  production. Given that c-Fos mediated  
330 Candidalysin-induced IL-1 $\beta$  production by BV-2 cells (**Fig. 6e,f**), we measured c-Fos  
331 expression in WT and *Card9*<sup>-/-</sup> microglia by immunoblot and found significantly decreased c-  
332 Fos expression in *Card9*<sup>-/-</sup> microglia (**Fig. 7d**).

333  
334 We next examined the NLRP3 inflammasome in FACS-sorted WT and *Card9*<sup>-/-</sup> microglia. We  
335 focused on NLRP3 because CARD9 was reported to negatively regulate NLRP3 activation

336 during macrophage *Salmonella* infection<sup>30</sup>, and we recently showed that Candidalysin  
337 activates NLRP3 in bone marrow-derived macrophages<sup>31</sup>. We found significantly decreased  
338 NLRP3 protein expression in *Card9*<sup>-/-</sup> microglia (**Fig. 7e**). Of interest, *Nlrp3*<sup>-/-</sup> animals had  
339 significantly decreased neutrophil accumulation to the *C. albicans*-infected brain and increased  
340 fungal load post-infection, consistent with a potential role of Card9-dependent NLRP3-  
341 inflammasome activation for protective neutrophil influx in the fungal-infected CNS (**Fig. 7f**).  
342 Together, microglia require CARD9 for c-Fos activation and for production of mature IL-1 $\beta$  via  
343 *Il1b* transcriptional regulation and inflammasome activation, to activate the IL-1 $\beta$ –CXCL1 axis  
344 in response to fungal invasion.

#### 345 346 **Microglial CARD9 Deletion Causes CNS Fungal Invasion**

347 We next directly examined the impact of genetic *Card9* deletion specifically within microglia by  
348 utilizing mice expressing tamoxifen-inducible Cre recombinase under the *Cx3cr1* promoter  
349 (*Cx3cr1*<sup>CreER</sup>)<sup>32</sup>. These mice has been used to genetically manipulate long-lived CX3CR1<sup>+</sup>  
350 microglia while leaving short-lived CX3CR1<sup>+</sup> monocytes and monocyte-derived macrophages  
351 unaffected. We bred *Cx3cr1*<sup>CreER</sup> animals to *Card9*-floxed mice<sup>11</sup>, tamoxifen-pulsed the  
352 progeny to activate Cre expression and waited 4-6 weeks to allow replenishment of short-lived  
353 non-microglia CX3CR1<sup>+</sup> cells from the bone marrow, while long-lived microglia remained  
354 *Card9*-deficient (**Supplementary Fig. S6**). *C. albicans* infection of *Card9*<sup>fl/fl</sup>*Cx3cr1*<sup>CreER+/-</sup>  
355 animals revealed a significant dependence on *Card9* expression by the long-lived CX3CR1<sup>+</sup>  
356 cellular compartment for control of fungal brain growth (**Fig. 8a**), while fungal control in the  
357 kidney was unaffected in microglia-specific conditional *Card9*<sup>-/-</sup> mice (**Fig. 8a**).

358

359 To analyze whether the susceptibility to brain infection in *Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER+/-</sup>* mice was  
360 related to a neutrophil recruitment defect, we quantified neutrophils within the infected brains of  
361 *Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER+/-</sup>* mice and their Cre-negative littermates. We found that microglial  
362 deletion of *Card9* significantly reduced the protective early influx of neutrophils into the fungal-  
363 infected brain (**Fig. 8b**), which correlated with significantly decreased expression of microglial  
364 pro-IL1 $\beta$  and CXCL1 in the conditional *Card9<sup>-/-</sup>* mice (**Fig. 8c**). Together, our data shows that  
365 CARD9-expressing microglia orchestrate control of fungal brain invasion, in part by responding  
366 to fungus-secreted Candidalysin, to produce IL-1 $\beta$ -induced CXCL1, which recruits CXCR2-  
367 expressing neutrophils that are required for CNS fungal clearance (**Supplementary Fig. S7**).

## Discussion

Herein, we demonstrate the critical contribution of CARD9-mediated IL-1 $\beta$  and CXCL1 in recruiting protective neutrophils to the fungal-infected CNS. We identify microglia as major producers of CARD9-dependent IL-1 $\beta$  and CXCL1 during *C. albicans* CNS invasion and the fungal-secreted toxin Candidalysin as a critical pathogen-derived factor activating this pathway. Our study offers novel insights into the network of host and fungal factors that protect against CNS fungal invasion and unveil the mechanism of CNS fungal susceptibility in inherited CARD9-deficiency.

Systemic candidiasis is a leading cause of nosocomial bloodstream infection with mortality >50% despite therapy<sup>33</sup>. Neutropenia is the major predisposing factor for systemic candidiasis and *Candida* CNS invasion in particular<sup>5, 34</sup>. Moreover, CNS invasion is prevalent during systemic candidiasis in low-birth weight neonates and also occurs as an iatrogenic complication post-neurosurgical procedures<sup>35, 36</sup>. Strikingly, CARD9-deficiency is a primary immunodeficiency disorder (PID) characterized by heightened susceptibility to fungal infections of which CNS candidiasis is a hallmark<sup>2, 3</sup>. CARD9-deficiency is the only known PID that causes fungal-specific infection susceptibility without other infectious or non-infectious manifestations, and the only PID that causes fungal disease in which CNS is a primary target tissue<sup>17</sup>. We previously demonstrated that *Candida* CNS disease in CARD9-deficiency is caused by a fungal- and brain-specific defect in neutrophil recruitment<sup>5</sup>. CNS neutropenia is now confirmed in several CARD9-deficient patients with CNS candidiasis<sup>7, 37, 38</sup>. Nonetheless,

390 how CARD9 mediates protective neutrophil trafficking into the fungal-infected CNS remained  
391 unclear.

392

393 Our analysis of mice deficient in several CLR, cytokine and chemokine circuits uncovered a)  
394 the functional redundancy among CLRs, which may suggest the presence of yet-undiscovered  
395 CARD9-coupled receptors for tissue-specific protection against fungal invasion; b) the  
396 indispensable role of the CARD9 partner MALT1 in controlling CNS fungal invasion  
397 independent of neutrophil recruitment, which implies that *MALT1*<sup>-/-</sup> patients may be at risk for  
398 CNS fungal disease; and c) the critical contribution of IL-1 $\beta$ –CXCL1-mediated neutrophil  
399 recruitment for control of CNS fungal invasion. CXCR2 was known to mediate neutrophil  
400 trafficking during viral infection, parasitic meningitis<sup>39</sup> and fungal pneumonia<sup>40</sup>, and herein we  
401 reveal its importance for recruiting neutrophils during *C. albicans* CNS infection, principally  
402 through binding CXCL1. In contrast, CCR1, CXCR1 and LTB4R1 are dispensable despite  
403 them regulating neutrophil recruitment and function in other *C. albicans*-infected tissues<sup>13, 14, 15</sup>.  
404 These studies further underscore the organ- and context-specific dependence on chemotactic  
405 molecules for protective host immunity.

406

407 We showed that IL-1 $\beta$  is required for CXCL1 induction, in line with earlier work which showed  
408 IL-1 $\beta$ –induced CXCL1 production controlling neutrophil accumulation during bacterial  
409 peritonitis and autoimmune, traumatic or bacterial neuroinflammation<sup>10, 41, 42</sup>. Importantly,  
410 microglia are the primary myeloid cellular source of IL-1 $\beta$ -dependent CXCL1 production *in*  
411 *vivo*. During oral candidiasis, IL-1R is also required for neutrophil accumulation to the oral  
412 mucosa<sup>8</sup>, as we have shown for systemic infection in the brain. However, further attesting to

413 the presence of tissue-specific anti-*Candida* immune response cues, the IL-1R-dependent  
414 response in the oral epithelium is largely controlled by IL-1 $\alpha$  released by damaged  
415 keratinocytes<sup>8</sup>, whereas we found that IL-1 $\alpha$  plays a modest role in the control of brain fungal  
416 invasion. In fact, IL-1 $\alpha$  release by epithelial cells, in both the oral and vaginal mucosal barriers,  
417 is driven by exposure to the fungal secreted toxin Candidalysin<sup>19, 20, 21</sup>.

418

419 Candidalysin enables the establishment of *C. albicans* mucosal infections, since Candidalysin-  
420 deficient strains are avirulent in these models<sup>19, 21</sup>. In contrast, we found that Candidalysin-  
421 deficient strains are hyper-virulent for the brain, associated with decreased IL-1 $\beta$  and CXCL1  
422 production and impaired neutrophil recruitment. These results indicate that Candidalysin is not  
423 only a classical virulence factor, but also an immune modulator, which exerts context-specific  
424 effects on the immune system. We propose that this dual function of Candidalysin is the result  
425 of a co-evolutionary event; the fungus developed an efficient toxin to damage host  
426 membranes, and, in response, the host evolved a sensitive Candidalysin detection system to  
427 defend against this common mucosal pathogen. Whether Candidalysin is recognized by a  
428 specific microglial innate receptor to mediate the protective IL-1 $\beta$ –CXCL1 axis is unclear, since  
429 the toxin mediates cellular damage which could also activate glial cells. Therefore, identifying  
430 how host epithelial and immune cells recognize Candidalysin merits investigation.

431

432 We found that Candidalysin selectively activates microglia for IL-1 $\beta$  and CXCL1 production, a  
433 self-renewing macrophage population that contributes towards neuroinflammation in  
434 neurodegenerative disorders and promotes pathogen and dead cell clearance within the  
435 CNS<sup>43</sup>. Interestingly, downstream of Candidalysin-induced microglial IL-1 $\beta$  secretion, which

occurs via c-Fos activation, we show that additional signals derived from astrocytes acting *in trans* are required for microglia to secrete CXCL1. Whether direct microglia-astrocyte contact is required or astrocyte-derived soluble factors acting on microglia are needed remains unknown. Indeed, microglia are known to interact with astrocytes to drive or suppress inflammation<sup>44, 45</sup>. Therefore, the molecular factors that drive microglia-astrocyte cross-talk within the fungal-infected brain warrant further investigation.

Lastly, we examined the dependence on CARD9 for the microglia-mediated, IL-1 $\beta$ -CXCL1-dependent pathway that recruits protective neutrophils, using fully Card9-deficient and conditional microglia-specific *Card9*<sup>-/-</sup> mice. We show that CARD9 is critical for c-Fos activation and for the production of both IL-1 $\beta$  and CXCL1 by microglia in the infected CNS operating at the levels of both transcriptional pro-IL-1 $\beta$  regulation and inflammasome activation for IL-1 $\beta$  generation, with NLRP3 being at least partly involved, as shown with *Microsporum* infection<sup>46</sup>. Together, these data shed light into the pathogenesis of inherited CARD9-deficiency by outlining a pathway of CARD9-dependent microglial production of sequential IL-1 $\beta$  and CXCL1 that recruits protective neutrophils into the fungal-infected CNS.

Future studies should examine how Card9 promotes microglial innate functions beyond orchestrating neutrophil recruitment such as fungal uptake and killing. Of note, the phenotype of the microglia-specific conditional knockout mice is less severe than that of *Card9*<sup>-/-</sup> mice, which may reflect the important role of astrocytes, which express Card9 post-*Candida* infection<sup>13</sup>, in priming microglial CXCL1 production. Future work should also examine the potentially differential tissue-specific dependence on Card9 for neutrophil recruitment by non-

459 CNS tissue-resident macrophages, such as Kupffer cells, as previously shown for  
460 macrophages and dendritic cells<sup>47</sup>, which will help further understand the CNS-specificity of  
461 fungal disease in CARD9-deficiency. Beyond understanding the pathogenesis of inherited  
462 CARD9-deficiency, our findings have important implications for recognizing the potential fungal  
463 infection risk in patients who are increasingly receiving Syk inhibitors for the treatment of  
464 autoimmune and malignant diseases<sup>48, 49</sup>. Surveillance of Syk inhibitor-treated patients and  
465 research in conditional Syk-deficient mice will help determine their CNS fungal disease risk.  
466  
467 In summary, we present evidence of an intricate host immune pathway that protects the CNS  
468 from invading fungi. This work uncovers the complex interactions occurring between the host  
469 and the most common human fungal pathogen within the CNS, and sheds novel mechanistic  
470 light into the pathogenesis of inherited CARD9-deficiency.



471 **Acknowledgements**

472 This work was supported by the Intramural Research Program of the National Institute of  
473 Allergy and Infectious Disease, National Institutes of Health, as well as NIH grants awarded to  
474 T.M.H (R01 093808), S.G.F (R01AI124566) and S.R.L (R01CA161373). Additional funding  
475 was provided by the Burroughs Wellcome Fund (awarded to T.M.H), the Wellcome Trust  
476 (102705, 097377; awarded to G.D.B), the MRC Centre for Medical Mycology and the  
477 University of Aberdeen (MR/N006364/1; awarded to G.D.B). The authors additionally thank C.  
478 Huaman for care and screening of the *Malt1*<sup>-/-</sup> mice, which were a kind gift to B.C.S. from T.  
479 Mak and the University Health Network (Canada), and D. McGavern and F. Crews for  
480 providing the murine glial cell lines.

481

482 **Authors' Contributions**

483 R.A.D, B.H, J.R.N, T.M.H and M.S.L designed the study. R.A.D, M.S, V.O, B.Z, and I.M.D  
484 performed the experiments. B.C.S, A.C.B, K.D.M-B, S.A.L, Y.I, S.G.F, G.D.B, B.H, J.R.N and  
485 T.M.H provided key reagents/mouse lines and intellectual input into the experimental design  
486 regarding their use. R.A.D. and M.S.L assembled and wrote the manuscript.

487

488 **Data Availability**

489 The data that support the findings of this study are available from the corresponding authors  
490 upon request.

## References

1. Lionakis, M.S. & Levitz, S.M. Host control of fungal infections: lessons from basic studies and human cohorts. *Ann Rev Immunol* **36**, 157-191 (2017).
2. Drummond, R.A. & Lionakis, M.S. Mechanistic insights into the role of C-type lectin receptor/CARD9 signaling in human antifungal immunity. *Front Cell Infect Microbiol* **6**, <http://dx.doi.org/10.3389/fcimb.2016.00039> (2016).
3. Glocker, E.O., Hennigs, A., Nabavi, M., Schaffer, A.A., Woellner, C. *et al.* A homozygous CARD9 mutation in a family with susceptibility to fungal infections. *N Engl J Med* **361**, 1727-1735 (2009).
4. Lanternier, F., Pathan, S., Vincent, Q.B., Liu, L., Cypowyj, S. *et al.* Deep dermatophytosis and inherited CARD9 deficiency. *N Engl J Med* **369**, 1704-1714 (2013).
5. Drummond, R.A., Collar, A.L., Swamydas, M., Rodriguez, C.A., Lim, J.K. *et al.* CARD9-dependent neutrophil recruitment protects against fungal invasion of the central nervous system. *PLoS Pathog* **11**, e1005293 (2015).
6. Li, X., Utomo, A., Cullere, X., Choi, M.M., Milner, D.A., Jr. *et al.* The  $\beta$ -glucan receptor Dectin-1 activates the integrin Mac-1 in neutrophils via Vav protein signaling to promote *Candida albicans* clearance. *Cell Host Microbe* **10**, 603-615 (2011).
7. Drewniak, A., Gazendam, R.P., Tool, A.T.J., van Houdt, M., Jansen, M.H. *et al.* Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. *Blood* **121**, 2385-2392 (2013).
8. Altmeier, S., Toska, A., Sparber, F., Teixeira, A., Halin, C. *et al.* IL-1 coordinates the neutrophil response to *C. albicans* in the oral mucosa. *PLOS Pathog* **12**, e1005882 (2016).
9. Karki, R., Man, S.M., Malireddi, R.K.S., Gurung, P., Vogel, P. *et al.* Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against *Aspergillus* infection. *Cell Host Microbe* **17**, 357-368 (2015).
10. Biondo, C., Mancuso, G., Midiri, A., Signorino, G., Domina, M. *et al.* The interleukin-1 $\beta$ /CXCL1/2/neutrophil axis mediates host protection against group B Streptococcal infection. *Infect Immun* **82**, 4508-4517 (2014).
11. Nemeth, T., Futosi, K., Sitaru, C., Ruland, J. & Mocsai, A. Neutrophil-specific deletion of the CARD9 gene expression regulator suppresses autoantibody-induced inflammation in vivo. *Nat Commun* **7**, 11004 (2016).

12. Wang, X., Zhang, R., Wu, W., Song, Y., Wan, Z. *et al.* Impaired specific antifungal immunity in CARD9-deficient patients with phaeohyphomycosis. *J Invest Dermatol* **138**, 607-617 (2018).
13. Lionakis, M.S., Fischer, B.G., Lim, J.K., Swamydas, M., Wan, W. *et al.* Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. *PLoS Pathog* **8**, e1002865 (2012).
14. Lee, E.K.S., Gillrie, M.R., Li, L., Arnason, J.W., Kim, J.H. *et al.* Leukotriene B4-mediated neutrophil recruitment causes pulmonary capillaritis during lethal fungal sepsis. *Cell Host Microbe* **23**, 121-133.e124 (2018).
15. Swamydas, M., Gao, J.-L., Break, T.J., Johnson, M.D., Jaeger, M. *et al.* CXCR1-mediated neutrophil degranulation and fungal killing promote *Candida* clearance and host survival. *Sci Trans Med* **8**, 322ra310-322ra310 (2016).
16. Ngo, L.Y., Kasahara, S., Kumasaka, D.K., Knoblaugh, S.E., Jhingran, A. *et al.* Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis. *J Infect Dis* **209**, 109-119 (2014).
17. Erwig, L.P. & Gow, N.A.R. Interactions of fungal pathogens with phagocytes. *Nature Rev Microbiol* **14**, 163 (2016).
18. Zheng, X., Wang, Y. & Wang, Y. Hgc1, a novel hypha-specific G1 cyclin-related protein regulates *Candida albicans* hyphal morphogenesis. *EMBO J* **23**, 1845-1856 (2004).
19. Moyes, D.L., Wilson, D., Richardson, J.P., Mogavero, S., Tang, S.X. *et al.* Candidalysin is a fungal peptide toxin critical for mucosal infection. *Nature* **532**, 64-68 (2016).
20. Verma, A.H., Richardson, J.P., Zhou, C., Coleman, B.M., Moyes, D.L. *et al.* Oral epithelial cells orchestrate innate type 17 responses to *Candida albicans* through the virulence factor candidalysin. *Sci Immunol* **2** (2017).
21. Richardson, J.P., Willems, H.M.E., Moyes, D.L., Shoaie, S., Barker, K.S. *et al.* Candidalysin drives epithelial signaling, neutrophil recruitment, and immunopathology at the vaginal mucosa. *Infect Immun*, 10.1128/IAI.00645-00617 (2017).
22. Naglik, J.R., Challacombe, S.J. & Hube, B. *Candida albicans* secreted aspartyl proteinases in virulence and pathogenesis. *Microbiol Mol Biol Rev* **67**, 400-428 (2003).
23. Gabrielli, E., Sabbatini, S., Roselletti, E., Kasper, L., Perito, S. *et al.* In vivo induction of neutrophil chemotaxis by secretory aspartyl proteinases of *Candida albicans*. *Virulence* **7**, 819-825 (2016).

24. Pericolini, E., Gabrielli, E., Amacker, M., Kasper, L., Roselletti, E. *et al.* Secretory aspartyl proteinases cause vaginitis and can mediate vaginitis caused by *Candida albicans* in mice. *mBio* **6**, e00724-00715 (2015).
25. Henn, A., Lund, S., Hedtjarn, M., Schrattenholz, A., Porzgen, P. *et al.* The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. *Altex-Alternativen Zu Tierexperimenten* **26**, 83-94 (2009).
26. Hennessy, E., Griffin, É.W. & Cunningham, C. Astrocytes are primed by chronic neurodegeneration to produce exaggerated chemokine and cell infiltration responses to acute stimulation with the cytokines IL-1 $\beta$  and TNF- $\alpha$ . *J Neurosci* **35**, 8411-8422 (2015).
27. Pineau, I., Sun, L., Bastien, D. & Lacroix, S. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. *Brain Behav Immun* **24**, 540-553 (2010).
28. Omari, K.M., John, G., Lango, R. & Raine, C.S. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. *Glia* **53**, 24-31 (2005).
29. Poeck, H., Bscheider, M., Gross, O., Finger, K., Roth, S. *et al.* Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 $\beta$  production. *Nature Immunol* **11**, 63 (2009).
30. Pereira, M., Toulomousis, P., Wright, J., P Monie, T. & Bryant, C.E. CARD9 negatively regulates NLRP3-induced IL-1 $\beta$  production on *Salmonella* infection of macrophages. *Nature Commun* **7**, 12874-12874 (2016).
31. Kasper, L., König, A., Koenig, P.-A., Gresnigt, M.S., Westman, J. *et al.* The fungal peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes. *Nature Commun* **9**, 4260 (2018).
32. Parkhurst, C.N., Yang, G., Ninan, I., Savas, J.N., Yates, J.R. *et al.* Microglia promote learning-dependent synapse formation through BDNF. *Cell* **155**, 1596-1609 (2013).
33. Pappas, P.G., Lionakis, M.S., Arendrup, M.C., Ostrosky-Zeichner, L. & Kullberg, B.J. Invasive candidiasis. *Nat Rev Dis Primers* **4**, 18026 (2018).
34. Lionakis, M.S., Netea, M.G. & Holland, S.M. Mendelian genetics of human susceptibility to fungal infection. *Cold Spring Harbor Perspect Med* **4** (2014).
35. McCarthy, M.W., Kalasauskas, D., Petraitis, V., Petraitiene, R. & Walsh, T.J. Fungal infections of the central nervous system in children. *J Pediatric Infect Dis Soc*, <https://doi.org/10.1093/jpids/pix1059> (2017).

- 626 36. Drummond, R.A. & Lionakis, M.S. Candidiasis of the central nervous system in  
627 neonates and children with primary immunodeficiencies. *Curr Fungal Infect Rep* **12**, 92-  
628 97 (2018).
- 629
- 630 37. Cetinkaya, P.G., Ayvaz, D.C., Karaatmaca, B., Gocmen, R., Söylemezoğlu, F. *et al.* A  
631 young girl with severe cerebral fungal infection due to card 9 deficiency. *Clin. Immunol.*  
632 **191**, 21-26 (2018).
- 633
- 634 38. Lanternier, F., Mahdavian, S.A., Barbati, E., Chaussade, H., Koumar, Y. *et al.* Inherited  
635 CARD9 deficiency in otherwise healthy children and adults with *Candida* species-  
636 induced meningoencephalitis, colitis, or both. *J Allergy Clin Immunol* **135**, 1558-1568  
637 (2015).
- 638
- 639 39. Del Rio, L., Bennouna, S., Salinas, J. & Denkers, E.Y. CXCR2 deficiency confers  
640 impaired neutrophil recruitment and increased susceptibility during *Toxoplasma gondii*  
641 infection. *J Immunol* **167**, 6503 (2001).
- 642
- 643 40. Bonnett, C.R., Cornish, E.J., Harmsen, A.G. & Burritt, J.B. Early neutrophil recruitment  
644 and aggregation in the murine lung inhibit germination of *Aspergillus fumigatus* conidia.  
645 *Infect Immun* **74**, 6528-6539 (2006).
- 646
- 647 41. Lévesque, S.A., Paré, A., Mailhot, B., Bellver-Landete, V., Kébir, H. *et al.* Myeloid cell  
648 transmigration across the CNS vasculature triggers IL-1 $\beta$ -driven neuroinflammation  
649 during autoimmune encephalomyelitis in mice. *J Exp Med* **213**, 929-949 (2016).
- 650
- 651 42. Hanamsagar, R., Aldrich, A. & Kielian, T. Critical role for the AIM2 inflammasome during  
652 acute CNS bacterial infection. *J Neurochem* **129**, 704-711 (2014).
- 653
- 654 43. Prinz, M., Erny, D. & Hagemeyer, N. Ontogeny and homeostasis of CNS myeloid cells.  
655 *Nat Immunol* **18**, 385-392 (2017).
- 656
- 657 44. Shinozaki, Y., Shibata, K., Yoshida, K., Shigetomi, E., Gachet, C. *et al.* Transformation  
658 of astrocytes to a neuroprotective phenotype by microglia via P2Y1 receptor  
659 downregulation. *Cell Rep* **19**, 1151-1164 (2017).
- 660
- 661 45. Rothhammer, V., Borucki, D.M., Tjon, E.C., Takenaka, M.C., Chao, C.-C. *et al.*  
662 Microglial control of astrocytes in response to microbial metabolites. *Nature* **557**, 724-  
663 728 (2018).
- 664
- 665 46. Mao, L., Zhang, L., Li, H., Chen, W., Wang, H. *et al.* Pathogenic fungus *Microsporum*  
666 *canis* activates the NLRP3 inflammasome. *Infect Immun* **82**, 882 (2014).
- 667
- 668 47. Goodridge, H.S., Shimada, T., Wolf, A.J., Hsu, Y.-M.S., Becker, C.A. *et al.* Differential  
669 use of CARD9 by Dectin-1 in macrophages and dendritic cells. *J Immunol* **182**, 1146-  
670 1154 (2009).
- 671

- 672 48. Weinblatt, M.E., Kavanaugh, A., Genovese, M.C., Musser, T.K., Grossbard, E.B. *et al.*  
673 An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. *N Eng J Med* **363**,  
674 1303-1312 (2010).  
675  
676 49. Flynn, R., Allen, J.L., Luznik, L., MacDonald, K.P., Paz, K. *et al.* Targeting Syk-activated  
677 B cells in murine and human chronic graft-versus-host disease. *Blood* **125**, 4085-4094  
678 (2015).  
679  
680

## 681 **Methods**

682

### 683 **Mice**

684 Animals (males and females) were used at 8-12 weeks of age and were maintained in  
685 individually ventilated cages under specific pathogen-free conditions at the 14BS facility at the  
686 National Institutes of Health (Bethesda, MD, USA), the Memorial Sloan Kettering Cancer  
687 Center Comparative Medicine Shared Resources (New York, NY, USA), or the Medical  
688 Research Facility at the University of Aberdeen (UK). The following strains (and their  
689 respective WT controls/littermates) were obtained from the NIAID Taconic contract; *Cxcr2*<sup>-/-</sup>,  
690 *Il1r*<sup>-/-</sup>, *Ltb4r1*<sup>-/-</sup>, *Fpr1*<sup>-/-</sup>. All other strains and their respective controls/littermates were bred in-  
691 house at the NIH (*Clec7a*<sup>-/-</sup>, *Clec4n*<sup>-/-</sup>, *Clec4e*<sup>-/-</sup>, *Myd88*<sup>-/-</sup>, *Ccr1*<sup>-/-</sup>, *Cxcr1*<sup>-/-</sup>, *Cxcl1*<sup>-/-</sup>, *Il1a*<sup>-/-</sup>,  
692 *Il1b*<sup>-/-</sup>, *Il1a*<sup>-/-</sup>*Il1b*<sup>-/-</sup>, *Nlrp3*<sup>-/-</sup>, *Card9*<sup>fl/fl</sup>*Cx3CR1*<sup>CreER+/-</sup>), Memorial Sloan-Kettering Cancer Center  
693 (*Clec7a*<sup>-/-</sup>*Fcer1g*<sup>-/-</sup>), University of Aberdeen (*Clec4d*<sup>-/-</sup>), or USUHS (*Malt1*<sup>-/-</sup>)<sup>51</sup>. Mice  
694 homozygous for the *Card9*<sup>tm1a</sup> allele were purchased from the Wellcome Trust Sanger Institute  
695 (EUCOMM Project No. 44813), and these animals were bred with the FLPer deleter strain  
696 (Jackson Laboratories) to remove the FRT-flanked knock-out first cassette, generating  
697 *Card9*<sup>tm1c</sup> homozygous mice (referred to as *Card9*<sup>fl/fl</sup> in this manuscript)<sup>52,53</sup>. Homozygous  
698 *Card9*<sup>fl/fl</sup> animals were bred with heterozygous *Cx3cr1*<sup>CreER</sup> transgenic animals (Jackson  
699 Laboratories) to generate *Card9*<sup>fl/fl</sup>*Cx3cr1*<sup>CreER+/-</sup> mice and littermate controls. Soon after  
700 weaning (~5-6 weeks old), *Card9*<sup>fl/fl</sup>*Cx3cr1*<sup>CreER+/-</sup> mice and their controls were treated with two  
701 10mg doses of tamoxifen (Sigma) administered in corn oil by oral gavage, given 48 h apart.  
702 After 4-6 weeks, these animals were infected and analyzed as outlined in the Figure legends.

703 All experimentation conformed to conditions approved by the Animal Care and Use Committee  
704 of the National Institute of Allergy and Infectious Diseases.

705

#### 706 **Candidiasis Model and Fungal Burden Determination**

707 *Candida albicans* strains used in this study were SC5314, BWP17, *ece1* $\Delta/\Delta$ , *ece1* $\Delta/\Delta$ +*ECE1*,  
708 *ece1* $\Delta/\Delta$ +*ECE1* $\Delta_{184-279}$ <sup>19</sup>, CAI4+Clp10 and *sap4/5/6* $\Delta/\Delta$ , and *hgc1* $\Delta/\Delta$  and *hgc1* $\Delta/\Delta$  + *HGC1*<sup>18</sup>.

709 Yeast was serially passaged three times in YPD broth, grown at 30°C with shaking for 18-24 h  
710 at each passage. Yeast cells were washed in PBS, counted, and injected intravenously via the  
711 lateral tail vein. Animals were infected with  $1.3 \times 10^5$  colony forming units (CFU) for analysis at  
712 24 h post-infection, or  $7 \times 10^4$  CFU for analysis at 72 h post-infection, unless otherwise stated  
713 in the corresponding Figure legends. For analysis of brain fungal burdens, animals were  
714 euthanized and brains weighed, homogenized in PBS, and serially diluted before plating onto  
715 YPD agar supplemented with Penicillin/Streptomycin (Invitrogen). Colonies were counted after  
716 incubation at 37°C for 24-48 h.

717

#### 718 **Analysis of Brain Neutrophil Recruitment by FACS**

719 Leukocytes were isolated from brains using previously described methods<sup>54</sup>, resuspended in  
720 PBS and stained with Live/Dead fluorescent dye (Invitrogen) for 10 min on ice. Cells were then  
721 stained with fluorophore-conjugated antibodies in the presence of anti-CD16/32 and 0.5% BSA  
722 for 30 min on ice. Samples were washed in PBS/0.5% BSA/0.01% sodium azide and acquired  
723 using the BD Fortessa instrument equipped with BD FACS Diva software (BD Biosciences).  
724 FlowJo (TreeStar) was used for the final analysis. Anti-mouse antibodies used in this study



725 were: CD45 (30-F11), CD11b (M1/70), both from eBiosciences, and Ly6G (1A8), Ly6C (AL-  
726 21), both from BD Biosciences.

727

## 728 **Histology**

729 Brains were removed from infected mice at the indicated time points and fixed in 10% formalin  
730 for 24 h before embedding in paraffin wax. Tissue sections were stained with periodic acid-  
731 Schiff (PAS).

732

## 733 **Measurement of Cytokines and Chemokines in Brain Homogenates**

734 Infected brains were isolated at 24 h post-infection and homogenized in 1 mL PBS  
735 supplemented with 0.05% Tween20 and protease inhibitor cocktail (Roche). Homogenized  
736 brains were centrifuged twice to remove debris and resulting supernatants snap-frozen on dry  
737 ice and stored at –80 °C prior to analysis. IL-1 $\beta$  and CXCL1 concentrations in the  
738 homogenates was determined by ELISA (R&D Systems), following the manufacturers'  
739 instructions.

740

## 741 **Ex Vivo Restimulations and Intracellular FACS Analysis**

742 Animals were infected with  $2 \times 10^5$  CFU of the indicated *C. albicans* strains intravenously, and  
743 brain leukocytes isolated 24 h later. For these experiments, brains were first digested in RPMI  
744 supplemented with 0.8 mg/mL Dispase (Gibco), 0.2mg/mL Collagenase Type 4 (Worthington),  
745 and 0.1 mg/mL DNase (Roche) at 37 °C for 30 min, then pipetted vigorously to create a  
746 homogenous suspension. These suspensions were centrifuged (1500 rpm, 5 min, 4 °C),  
747 pellets resuspended in 5 mL 40% Percoll (GE Healthcare) and centrifuged again at 1700 rpm

for 20 min at 4 °C to remove myelin. Cell pellets were washed in RPMI supplemented with 10% heat-inactivated fetal bovine serum and Penicillin/Streptomycin (Invitrogen), and added to FACS tubes for stimulations. Cells were incubated for 4 h at 37 °C in the presence of 5 µg/mL Brefeldin A (Sigma) and, where indicated, 1 µg/mL LPS (Sigma) or 62.5 µg/mL depleted zymosan (Sigma). After stimulation, cells were washed in PBS and stained for surface markers as above. Fixation/permeabilization was performed with the eBioscience Foxp3 staining kit, and staining for CXCL1 (IC4532R, from R&D Systems) or pro-IL-1β (NJTEN3; from eBioscience) performed overnight at 4 °C. Samples were washed once in PBS/0.5% BSA/0.01% sodium azide prior to acquisition using the BD Fortessa instrument equipped with BD FACS Diva software (BD Biosciences). FlowJo (TreeStar) was used for the final analysis. CXCL1<sup>+</sup> and pro-IL-1β<sup>+</sup> cells were determined by employing similar staining and gating in animals deficient in these mediators (*Cxcl1*<sup>-/-</sup>, *Il1b*<sup>-/-</sup>) as negative controls.

760

#### 761 **Cell Culture and Candidalysin Stimulations**

BV-2 cells were kindly provided by F. Crews (University of North Carolina School of Medicine). C8-D1A astrocytes were kindly provided by D. McGavern (NINDS, NIH). BV-2 were maintained at 37 °C, 5% CO<sub>2</sub> in RPMI supplemented with L-glutamine and HEPES (pH 7.0 – 7.4; Corning), 10% heat-inactivated fetal bovine serum and Penicillin/Streptomycin (Invitrogen). DMEM media was used as the base media for C8-D1A culture, with the same supplements as listed above and cultured as for BV-2. For BV-2 single culture experiments, cells were lifted using cell scrapers and seeded into 24 well-plates at 5 × 10<sup>5</sup> cells/well (BV-2) and left to adhere for 2 h at 37°C with either: 50 ng/mL LPS (Sigma), T-5224 (APEX BIO) and/or SB203580 (Adipogen); see Figure legends for details of each experiment. After 2 h,

771 recombinant Candidalysin peptide (Peptide Protein Research) was added to the cells at the  
772 indicated concentrations and incubation at 37 °C continued. For co-culture experiments,  $3 \times$   
773  $10^5$  C8-D1A were added to each well of a 24 well-plate and incubated overnight at 37 °C. BV-2  
774 cells and Candidalysin were added as described above. In both types of experiments,  
775 supernatants or cells were collected at the indicated time points after Candidalysin addition  
776 and analyzed for IL-1 $\beta$  and CXCL1 by ELISA (R&D Systems), CXCL1 staining by intracellular  
777 flow cytometry, or by immunoblot.

778

### 779 **Immunoblot Analysis**

780 Whole cell lysates were suspended in RIPA buffer containing protease and phosphatase  
781 inhibitors (Thermo Scientific). Lysates were separated in SDS-PAGE and transferred to a  
782 nitrocellulose membrane, 0.2  $\mu$ m (Bio-Rad Laboratories). The membrane was incubated with  
783 the following primary antibodies: phospho-MPK1/MPK2 polyclonal [Ser296, Ser318] (Thermo  
784 Scientific) and c-Fos (Cell Signaling), IL-1 $\beta$  [3A6] (Cell Signaling), Caspase-1 p20 [Casper-1]  
785 (Adipogen Life Sciences) (Thermo Scientific), NLRP3 [D4D8T] (Cell Signaling). Normalization  
786 was performed by probing the membrane with  $\beta$ -Actin antibody (Cell Signaling).

787 Chemiluminescence detection was performed with Clarity<sup>TM</sup> Western ECL Substrate (Bio-Rad  
788 Laboratories), using the ChemiDoc<sup>TM</sup> MP Imaging System (Bio-Rad).

789

### 790 **FACS/MACS Sorting of Microglia**

791 Wild-type animals were infected with  $1.3 \times 10^5$  CFU SC5314 and euthanized at 24 h post-  
792 infection. Brains were digested as above and leukocytes stained with sterile antibodies<sup>55</sup>.

793 Ly6C<sup>hi</sup> monocytes (CD45<sup>hi</sup> CD11b<sup>+</sup> Ly6C<sup>hi</sup> Ly6G<sup>-</sup>) and microglia (CD45<sup>lo</sup> CD11b<sup>+</sup> Ly6G<sup>-</sup> Ly6C<sup>-</sup>)

794 were FACS-sorted into sterile sorting buffer (HBSS supplemented with 2 mM EDTA, 10 %  
795 FCS, 100 U/mL penicillin, 100 µg/mL streptomycin) using a FACS Aria instrument for  
796 downstream qRT-PCR and immunoblot analyses. Purity of cells were greater than >95%, on  
797 average. In some experiments (qRT-PCR of CLRs in brain-resident microglia; **Supplementary**  
798 **Fig. 1**), microglia were instead sorted by magnetic separation using anti-CD11b microbeads  
799 (Miltenyi). Cells were then centrifuged (1500 rpm 5 min, 4 °C) and resuspended in Trizol for  
800 RNA purification or RIPA buffer for downstream immunoblot analysis. Depending on the  
801 experiment, up to 5 animals were pooled for individual sorts, or individual mice were analyzed  
802 separately (see Figure legends for details).

803

#### 804 **Generation of cDNA and qRT-PCR**

805 RNA was extracted from sorted brain myeloid cells (defined using the gating strategy shown in  
806 **Supplementary Fig. 2**) using Trizol (Invitrogen) and the RNeasy kit (Qiagen) per the  
807 manufacturer's protocol. Purified RNA was used as a template for cDNA generation using the  
808 qScript cDNA SuperMix kit (Quanta Biosciences) with oligodT and random primers.  
809 Quantitative PCR was performed by TaqMan detection (PerfeCTa qPCR FastMix ROX;  
810 Quanta BioSciences) with the 7900HT Fast Real-Time PCR System (Applied Biosystems). All  
811 qPCR assays were performed in duplicate and the relative gene expression of each gene was  
812 determined after normalization with GAPDH transcript levels using the  $\Delta\Delta CT$  method. TaqMan  
813 primers/probes (*Clec7a*, *Clec4n*, *Clec4d*, *Clec4e*, *Il1b*, *Card9*, *Gapdh*) were predesigned by  
814 Applied Biosystems.

815

#### 816 **Statistics**

817 Statistical analyses were performed using GraphPad Prism 7.0 software. Details of individual  
818 tests are included in the figure legends. In general, data was tested for normal distribution by  
819 Kolmogorov-Smirnov normality test and analyzed accordingly by unpaired t-tests or Mann  
820 Whitney U-test. In cases where multiple data sets were analyzed, two-way ANOVA was used  
821 with Bonferroni correction. In all cases, *P* values <0.05 were considered significant.

822

#### 823 **Methods References:**

824

825 51. Ruland, J., Duncan, G.S., Wakeham, A., Mak, T.W. Differential requirement for Malt1 in T  
826 and B cell antigen receptor signaling. *Immunity* **19**(5), 749-58 (2003)

827

828 52. Tay, T.L., Mai, D., Dautzenberg, J., Fernandez-Klett, F., Lin, G. *et al.* A new fate mapping  
829 system reveals context-dependent random or clonal expansion of microglia. *Nat Neurosci* **20**,  
830 793-803 (2017)

831

832 53. Goldmann, T., Wieghofer, P., Muller, P.F., Wolf, Y., Varol, D. *et al.* A new type of microglia  
833 gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. *Nat Neurosci* **16**,  
834 1618-1626 (2013)

835

836 54. Lionakis, M.S., Lim, J.K., Lee, C.C.R. & Murphy, P.M. Organ-specific innate immune  
837 responses in a mouse model of invasive candidiasis. *J Innate Immun* **3**, 180-199 (2011)

838

839 55. Cougnoux, A., Drummond, R.A., Collar, A.L., Iben, J.R., Salman, A. *et al.* Microglia  
840 activation in Niemann-Pick disease, type C1 is amenable to therapeutic intervention. *Hum Mol*  
841 *Genet* **27**, 2076-2089 (2018)

842

## 843 Figure Legends

844

845 **Fig. 1: CARD9-coupled C-type lectin receptors functionally compensate for one another**  
846 **for protective neutrophil recruitment to the fungal-infected brain. a**, *Card9*<sup>-/-</sup> mice (n=4  
847 animals) and their wild-type controls (n=4 animals) were intravenously infected with *C. albicans*  
848 SC5314 and analyzed for neutrophil counts by flow cytometry at 24 h post-infection (left; dose:  
849  $1.3 \times 10^5$  CFU) and fungal growth within the brain at 72 h post-infection (right; dose:  $7 \times 10^4$   
850 CFU). **b**, Animals of the indicated genotype (WT n = 9 animals, *Clec7a*<sup>-/-</sup> n = 6 animals; WT n  
851 = 12 animals, *Clec4n*<sup>-/-</sup> n = 10 animals; WT n = 6 animals, *Clec4d*<sup>-/-</sup> n = 6 animals; WT n = 6  
852 animals, *Clec4e*<sup>-/-</sup> n = 8 animals; WT n = 10 animals, *Clec7a*<sup>-/-</sup>*Fcer1g*<sup>-/-</sup> n = 9 animals) were  
853 intravenously infected with *C. albicans* SC5314 ( $2 \times 10^5$  CFU for *Clec4d*<sup>-/-</sup> and *Clec7a*<sup>-/-</sup>  
854 *Fcer1g*<sup>-/-</sup> and their controls;  $1.3 \times 10^5$  all others) and analyzed for neutrophil counts by flow  
855 cytometry at 24 h post-infection and **c**, fungal burdens in the brain at 24 and 72 h post-infection  
856 (WT n = 9 animals, *Clec7a*<sup>-/-</sup> n = 6 animals; WT n = 10 animals, *Clec4n*<sup>-/-</sup> n = 10 animals; WT  
857 n = 10 animals, *Clec4d*<sup>-/-</sup> n = 10 animals; WT n = 6 animals, *Clec4e*<sup>-/-</sup> n = 4 animals; WT n =  
858 10 animals, *Clec7a*<sup>-/-</sup>*Fcer1g*<sup>-/-</sup> n = 9 animals). **d**, *Malt1*<sup>-/-</sup> mice and their littermate controls were  
859 infected as above and analyzed for fungal burdens in the brain (right; WT n = 7 animals, *Malt1*<sup>-/-</sup>  
860 <sup>-/-</sup> n = 5 animals) and neutrophil recruitment to the brain at 24 h post-infection (left; WT n = 5  
861 animals, *Malt1*<sup>-/-</sup> n = 5 animals). In all cases, 'wild type' refers to appropriate matched control  
862 animals for each knock-out line for gender, age and genetic background. Individual points  
863 represent different mice. Data is pooled from 2 independent experiments and is shown as  
864 mean +/- SEM, and analyzed by unpaired two-tailed t-test (panel **a** [left], **b**) or two-tailed Mann  
865 Whitney U-test (panel **a** [right], **c**, **d**). \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.005, \*\*\*\**P*<0.001.

866

867 **Fig. 2: IL-1 $\beta$  and CXCL1 are critical for protective neutrophil recruitment to the fungal-**  
868 **infected brain. a,b,** Animals deficient in elements of the IL-1R signaling pathway or **c,d,**  
869 chemokine receptors and their ligands, were infected and analyzed for neutrophil recruitment  
870 at 24 h post-infection (**a,c**) and control of fungal brain infection (**b,d**) as in Fig. 1. 'Wild type'  
871 refers to appropriate matched control animals for each knock-out line for gender, age and  
872 genetic background. Individual points represent different mice; (**a**) WT n = 8 animals, *Il1r*<sup>-/-</sup> n =  
873 8 animals; WT n = 7 animals, *Myd88*<sup>-/-</sup> n = 6 animals; WT n = 12 animals, *Il1a*<sup>-/-</sup> n = 12  
874 animals; WT n = 6 animals, *Il1b*<sup>-/-</sup> n = 6 animals; WT n = 8 animals, *Il1a*<sup>-/-</sup>*Il1b*<sup>-/-</sup> n = 6 animals.  
875 (**b**) WT n = 8 animals, *Il1r*<sup>-/-</sup> n = 7 animals; WT n = 7 animals, *Myd88*<sup>-/-</sup> n = 6 animals; WT n =  
876 3-8 animals, *Il1a*<sup>-/-</sup> n = 4-8 animals; WT n = 6 animals, *Il1b*<sup>-/-</sup> n = 6 animals; WT n = 6 animals,  
877 *Il1a*<sup>-/-</sup>*Il1b*<sup>-/-</sup> n = 6 animals. (**c**) WT n = 6 animals, *Ccr1*<sup>-/-</sup> n = 6 animals; WT n = 11 animals,  
878 *Cxcr1*<sup>-/-</sup> n = 11 animals; WT n = 14 animals, *Cxcr2*<sup>-/-</sup> n = 16 animals; WT n = 8 animals, *Cxcl1*<sup>-/-</sup>  
879 <sup>-/-</sup> n = 7 animals. (**d**) WT n = 6-7 animals, *Ccr1*<sup>-/-</sup> n = 6-7 animals; WT n = 7-10 animals, *Cxcr1*<sup>-/-</sup>  
880 n = 7-10 animals; WT n = 8-10 animals, *Cxcr2*<sup>-/-</sup> n = 7-10 animals; WT n = 6-8 animals, *Cxcl1*<sup>-/-</sup>  
881 <sup>-/-</sup> n = 5-7 animals. Data is pooled from 2-3 independent experiments and shown as mean +/-  
882 SEM, analyzed by unpaired two-tailed t-test (panel **a, c**) or two-tailed Mann Whitney U-test  
883 (panel **b, d**). \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.005, \*\*\*\**P*<0.001.

884

885 **Fig. 3: Production of CXCL1 is dependent on IL-1 $\beta$  in the fungal-infected brain. a,** Wild  
886 type (n = 6/7 animals), *Cxcl1*<sup>-/-</sup> (n = 5 animals) and *Il1b*<sup>-/-</sup> (n = 6 animals) animals were infected  
887 as in Fig. 1 and brains isolated at 24 h post-infection and analyzed for CXCL1 or IL-1 $\beta$   
888 production by ELISA. Data is pooled from 2 independent experiments and analyzed by



unpaired two-tailed t-test. **b**, The relative proportions of myeloid cell populations (gated within live CD45<sup>+</sup> singlets) in the uninfected (n = 6 animals) and 24 h infected WT (n = 6 animals) brain (left), and the relative proportion of myeloid cell populations producing CXCL1 (n = 3 animals) or pro-IL-1 $\beta$  (n = 9 animals) in the 24 h infected brain (right). For the latter, total CD45<sup>+</sup>CXCL1(or IL-1 $\beta$ )<sup>+</sup> cells were first gated and then cell types defined within this initial gate using lineage markers (see below), using samples from the unstimulated condition. Data is shown as the mean  $\pm$  SEM. **c**, Wild type (n = 3 animals) and *Il1b*<sup>-/-</sup> mice (n = 4 animals) were infected with  $2 \times 10^5$  *C. albicans* and brain cells analyzed for CXCL1 production by intracellular flow cytometry 24 h later. Brain cells were restimulated *ex vivo* with 62.5  $\mu$ g/mL depleted zymosan or 1  $\mu$ g/mL LPS for 4 h in the presence of 5  $\mu$ g/mL Brefeldin A. Representative plots from the LPS-stimulated condition are gated on microglia (top; CD45<sup>int</sup> Ly6G<sup>-</sup> CD11b<sup>+</sup>), Ly6C<sup>hi</sup> monocytes (middle; CD45<sup>hi</sup> Ly6C<sup>hi</sup> Ly6G<sup>-</sup> CD11b<sup>+</sup>) and neutrophils (bottom; CD45<sup>hi</sup> Ly6C<sup>int</sup> Ly6G<sup>hi</sup> CD11b<sup>+</sup>), showing corresponding *Cxcl1*<sup>-/-</sup> cells as gating controls. In all panels, 'wild type' refers to appropriate matched control animals for each knock-out line for gender, age and genetic background. Individual points represent different mice. Data shown as mean  $\pm$  SEM, and analyzed by unpaired two-tailed t-test. \**P*<0.05, \*\**P*<0.01.

**Fig. 4: Candidalysin is a specific hyphal-secreted factor promoting neutrophil recruitment and control of fungal growth in the brain. a,b,c,e**, Animals were infected with  $2 \times 10^5$  CFU of the indicated *C. albicans* strains (parental strains, closed symbols; deficient mutants, open symbols) and analyzed as in Fig. 1 for fungal burdens (*hgc1* $\Delta/\Delta$  n = 8 animals, *hgc1* $\Delta/\Delta$  + *HGC1* n = 7 animals; BWP17 n = 10 animals, *ece1* $\Delta/\Delta$  n = 11 animals, *ece1* $\Delta/\Delta$  + *ECE1* n = 10 animals, *ece1* $\Delta/\Delta$  + *ECE1* $\Delta_{184-279}$  n = 11 animals; CAI4 + Clp10 n = 6 animals,

912 *sap4/5/6Δ/Δ* + Clp10 n = 6 animals) and neutrophil recruitment (*hgc1Δ/Δ* n = 10 animals,  
 913 *hgc1Δ/Δ* + *HGC1* n = 10 animals; BWP17 n = 7 animals, *ece1Δ/Δ* n = 7 animals, *ece1Δ/Δ* +  
 914 *ECE1* n = 7 animals, *ece1Δ/Δ* + *ECE1*<sub>Δ184-279</sub> n = 11 animals; CAI4 + Clp10 n = 6 animals,  
 915 *sap4/5/6Δ/Δ* + Clp10 n = 7 animals). Histology shown in (c) is from 24 h post-infection, stained  
 916 with PAS. Scale bar is 50 μm. d, Whole brain homogenates from animals infected with  
 917 indicated strains were isolated at 24 h post-infection and analyzed for IL-1β and CXCL1 using  
 918 ELISA (BWP17 n = 8-10 animals, *ece1Δ/Δ* n = 8-10 animals, *ece1Δ/Δ* + *ECE1* n = 6-11  
 919 animals, *ece1Δ/Δ* + *ECE1*<sub>Δ184-279</sub> n = 7-11 animals). Individual points represent different mice.  
 920 Data is pooled from 2-4 independent experiments and shown as mean +/- SEM, analyzed by  
 921 unpaired two-tailed t-test, or two-tailed Mann Whitney U-test (panel a, left). \**P*<0.05, \*\**P*<0.01,  
 922 \*\*\**P*<0.005; ns = not significant.

923

924 **Fig. 5: Microglia produce IL-1β and CXCL1 in a Candidalysin-dependent manner.**

925 Animals were infected with wild-type *C. albicans* (BWP17; closed bars) or a Candidalysin-null  
 926 strain (*ece1Δ/Δ*; open bars), and brain cells isolated 24 h later. Brain leukocytes were  
 927 restimulated as in Fig. 3, and intracellular staining for a, IL-1β (unstimulated, n = 8 animals;  
 928 zymosan, n = 4 animals; LPS n = 6 animals) and b, CXCL1 (unstimulated, n = 12 animals;  
 929 zymosan, n = 6 animals; LPS n = 9 animals) was analyzed by flow cytometry. Box-and-whisker  
 930 plots show the minimum/maximum values (whiskers), the 25<sup>th</sup>/75<sup>th</sup> percentiles and the median.  
 931 Data is pooled from 2-4 independent experiments and analyzed by unpaired two-tailed t-tests.  
 932 \**P*<0.05, \*\**P*<0.01. Representative staining is shown for LPS-stimulated microglia (gated as in  
 933 Fig. 3) from wild-type mice infected with indicated strains, or BWP17-infected cytokine-  
 934 deficient mutants as control.

935

936 **Fig. 6: Candidalysin activates IL-1 $\beta$  production from microglia via p38-cFos signaling**

937 **and promotes CXCL1 production from microglia through interactions with astrocytes.**

938 BV-2 microglia were seeded into 24-well plates at  $5 \times 10^5$  per well and left to adhere for 2 h in

939 the presence of 50 ng/mL LPS (for priming) before the addition of purified Candidalysin at the

940 indicated concentrations. Cell culture supernatants were analyzed for **a**, IL-1 $\beta$  production or **b**,

941 LDH release after 24 h of stimulation. Data is shown with the mean  $\pm$  SEM, individual points

942 represent individual culture wells (n = 4). **c-d**, In some experiments, BV-2 cells were co-

943 cultured with  $3 \times 10^5$  C8-D1A astrocytes, and CXCL1 production analyzed in the supernatant

944 by ELISA (n = 10 individual culture wells) or by intracellular flow cytometry (n = 3-5 individual

945 culture wells; data shown with the mean). In **d**, microglia and astrocytes were distinguished by

946 CD45 staining, and CXCL1 production assessed within CD45<sup>+</sup> (microglia) and CD45<sup>-</sup>

947 (astrocyte) gates. Histogram is gated on CD45<sup>+</sup> microglia. **e**, To measure cFos and pMKP1/2

948 activation, BV-2 cells were stimulated with the indicated Candidalysin concentrations for 30 or

949 120 min and BV-2 cells then lysed and analyzed for cFos and pMKP1/2 by immunoblot,

950 normalizing to  $\beta$ -actin. Immunoblots shown are representative of 2 independent experiments. **f**,

951 BV-2 cells were cultured in the presence of the indicated cFos and p38 inhibitors for 2 h prior

952 to stimulating with 20  $\mu$ M Candidalysin, and IL-1 $\beta$  measured in the supernatant by ELISA after

953 24 h (data shown as mean  $\pm$  SEM; n = 6 individual culture wells). All data is pooled from 2

954 independent experiments and analyzed by one-way ANOVA. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.005$ ,

955 \*\*\*\* $P < 0.0001$ .

956

**Fig. 7: CARD9 is required for the production of IL-1 $\beta$ , via regulation of pro-IL-1 $\beta$  transcription and inflammasome activation, and of CXCL1 in the fungal-infected brain.**

**a,b,** *Card9*<sup>+/+</sup> (n = 13 animals) and *Card9*<sup>-/-</sup> (n = 13 animals) animals were infected with 2  $\times$  10<sup>5</sup> CFU wild-type *C. albicans* (BWP17), and brain cells isolated 24 h later. Brain leukocytes were restimulated as in Fig. 4, and intracellular staining for pro-IL-1 $\beta$  and CXCL1 analyzed by flow cytometry in total CD45<sup>+</sup> cells (LPS-stimulated condition shown) (**a**) or microglia alone, normalized to *Card9*<sup>+/+</sup> results (**b**). Panels **a,b** show pooled data from 4 independent experiments, analyzed with two-tailed unpaired t-test. Data shown as mean  $\pm$  SEM (**a**) or with minimum/maximum values (whiskers), the 25<sup>th</sup>/75<sup>th</sup> percentiles and the median (**b**). **c,** Microglia were FACS-sorted from pooled *Card9*<sup>+/+</sup> (n = 4 animals) and *Card9*<sup>-/-</sup> animals (n = 4 animals) at 24 h post-infection and analyzed by unpaired two-tailed t-test for *Il1b* expression by qRT-PCR, or **d,e,** the indicated proteins by immunoblot (Caspase and IL-1 $\beta$  blots; WT n = 6 animals, *Card9*<sup>-/-</sup> n = 7 animals; cFos blot; WT n = 10 animals, *Card9*<sup>-/-</sup> n = 10 animals; NLRP3 blot; WT n = 8 animals, *Card9*<sup>-/-</sup> n = 8 animals;). Graphs in (**d,e**) represent the band pixel density normalized to the wild type control, and are shown with mean  $\pm$  SEM and analyzed by unpaired two-tailed student t-tests. Example blots are representative of 3 independent FACS sorts/experiments; pooled data is shown in the graphs above. **f,** *Nlrp3*<sup>-/-</sup> animals and their wild-type controls were infected with 1.3  $\times$  10<sup>5</sup> CFU *C. albicans* and analyzed by unpaired two-tailed t-tests for neutrophil recruitment to the brain 24 h later (left; WT n = 9 animals, *Nlrp3*<sup>-/-</sup> n = 8 animals) and by two-tailed Mann-Whitney U-test for fungal brain burdens at 72 h post-infection (right; WT n = 14 animals, *Nlrp3*<sup>-/-</sup> n = 14 animals), as described in Fig. 1. \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.005.

980 **Fig. 8: CARD9 is required specifically in microglia for neutrophil recruitment and control**  
981 **of fungal invasion in the CNS. a**, *Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER-/-</sup>* and *Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER+/-</sup>* littermates  
982 (n=8-13) were tamoxifen-pulsed at 4-5 weeks of age, left to rest for 4-6 weeks and then  
983 infected with  $1.3 \times 10^5$  CFU *C. albicans* (SC5314) intravenously and analyzed for brain and  
984 kidney fungal burdens (*Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER-/-</sup>* n = 8-10 animals; *Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER+/-</sup>* n = 8  
985 animals), **b**, neutrophil recruitment to the brain at 24 h post-infection (*Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER-/-</sup>* n =  
986 13 animals; *Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER+/-</sup>* n = 9 animals), and **c**, intracellular staining for pro-IL-1 $\beta$  and  
987 CXCL1, as described in Fig. 3 (*Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER-/-</sup>* n = 8 animals; *Card9<sup>fl/fl</sup>Cx3cr1<sup>CreER+/-</sup>* n =  
988 8 animals). Data is pooled from 2-4 independent experiments and is shown as mean +/- SEM,  
989 analyzed by two-tailed Mann-Whitney U-tests (panel **a**) or two-tailed unpaired t-tests (panel **b**,  
990 **c**). \**P*<0.05, \*\**P*<0.01.